Joseph Group Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Joseph Group Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.69M	Buy	10,514 +25	+0.2%	+$11.7K	1.17%	31
2025 Q4	$4.76M	Buy	10,489 +121	+1%	+$52.2K	1.25%	27
2025 Q3	$4.06M	Buy	10,368 +2,608	+34%	+$1.09M	1.15%	30
2025 Q2	$3.45M	Buy	7,760 +634	+9%	+$292K	1.16%	34
2025 Q1	$3.45M	Buy	7,126 +704	+11%	+$328K	1.32%	26
2024 Q4	$2.59M	Buy	6,422 +750	+13%	+$348K	1.02%	35
2024 Q3	$2.64M	Buy	5,672 +855	+18%	+$411K	1.01%	29
2024 Q2	$2.26M	Buy	4,817 +426	+10%	+$185K	1.17%	25
2024 Q1	$1.84M	Buy	4,391 +643	+17%	+$272K	0.92%	38
2023 Q4	$1.53M	Buy	3,748 +310	+9%	+$115K	0.89%	31
2023 Q3	$1.2M	Buy	+3,438	New	+$1.2M	0.86%	38

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Joseph Group Capital Management's VRTX Position: Q1 2026 in Review

Joseph Group Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 0.24% in Q1 2026, buying an estimated $11.7K and bringing the position to 10,514 shares worth $4.69M. The position accounts for 1.17% of the portfolio, ranked #31.

Joseph Group Capital Management first reported a position in VRTX in Q3 2023 and has held it in 11 quarters since. The position peaked at $4.76M in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

Joseph Group Capital Management held 10,514 shares of Vertex Pharmaceuticals worth $4.69M as of Q1 2026.
Joseph Group Capital Management bought 25 Vertex Pharmaceuticals shares in Q1 2026, an estimated $11.7K.
Vertex Pharmaceuticals made up 1.17% of Joseph Group Capital Management's portfolio in Q1 2026, its #31 holding.
Joseph Group Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 11 quarters since.
Joseph Group Capital Management's Vertex Pharmaceuticals position peaked at $4.76M in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Joseph Group Capital Management's 13F filing for Q1 2026, filed 8 May 2026.